Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 274 publications
KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.
Journal: Cancers
Published: May 17, 2026
Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.
Journal: Journal of the National Cancer Institute
Published: April 28, 2026
Gastrointestinal malignancies in pregnancy: practical considerations.
Journal: Journal of gastrointestinal oncology
Published: February 13, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.
Journal: Future oncology (London, England)
Published: January 06, 2026
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 10, 2025
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma.
Journal: JCO precision oncology
Published: September 04, 2025
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors.
Journal: Cancer research communications
Published: August 29, 2025
ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer.
Journal: The oncologist
Published: June 16, 2025
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.
Journal: The oncologist
Published: May 15, 2025
Last Updated: 09/26/2026